The FDA is joining forces with Duke University Medical Center to address problems concerning the regulation of clinical trials. The public-private collaboration is expected to consider streamlining the structure of institutional review boards, the creation of accreditation programs for clinical researchers and the development of standardized electronic forms to gather health records.

Related Summaries